iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Ameriprise Financial Inc.

Ameriprise Financial Inc. raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 233.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,188 shares of the company's stock after purchasing an additional 143,672 shares during the period. Ameriprise Financial Inc. owned about 0.56% of iTeos Therapeutics worth $1,576,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Empowered Funds LLC increased its holdings in shares of iTeos Therapeutics by 5.0% in the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock valued at $530,000 after acquiring an additional 3,305 shares during the last quarter. Virtu Financial LLC increased its holdings in shares of iTeos Therapeutics by 84.3% in the 4th quarter. Virtu Financial LLC now owns 18,493 shares of the company's stock valued at $142,000 after acquiring an additional 8,460 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at about $142,000. US Bancorp DE increased its holdings in shares of iTeos Therapeutics by 40.1% in the 4th quarter. US Bancorp DE now owns 16,919 shares of the company's stock valued at $130,000 after acquiring an additional 4,843 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in iTeos Therapeutics during the 4th quarter worth approximately $1,159,000. Institutional investors and hedge funds own 97.16% of the company's stock.

Analyst Ratings Changes

ITOS has been the topic of a number of research reports. Wells Fargo & Company restated an "equal weight" rating and set a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. HC Wainwright downgraded iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Wedbush downgraded iTeos Therapeutics from an "outperform" rating to a "neutral" rating and raised their price target for the stock from $10.00 to $12.00 in a research note on Wednesday, May 28th. Leerink Partnrs downgraded iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Finally, Piper Sandler restated an "overweight" rating and set a $12.00 price target (down previously from $16.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, iTeos Therapeutics currently has an average rating of "Hold" and an average price target of $15.86.

Insiders Place Their Bets

In related news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the completion of the transaction, the insider now directly owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the transaction, the insider now owns 2,108,594 shares of the company's stock, valued at $16,995,267.64. The trade was a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 12.50% of the stock is owned by company insiders.

iTeos Therapeutics Stock Down 0.1%

Shares of iTeos Therapeutics stock traded down $0.01 during trading on Monday, reaching $10.01. The company's stock had a trading volume of 1,382,048 shares, compared to its average volume of 647,333. iTeos Therapeutics, Inc. has a 12-month low of $4.80 and a 12-month high of $18.13. The company has a market capitalization of $383.12 million, a P/E ratio of -3.18 and a beta of 1.39. The business has a 50 day moving average price of $6.99 and a 200-day moving average price of $7.39.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Research analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.